Cargando…
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic driver capable of initiating and maintaining the disease. Despite the remarkable efficacy of tyrosine kinase inhibitors (TK...
Autores principales: | Bavaro, Luana, Martelli, Margherita, Cavo, Michele, Soverini, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940932/ https://www.ncbi.nlm.nih.gov/pubmed/31817512 http://dx.doi.org/10.3390/ijms20246141 |
Ejemplares similares
-
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
por: Soverini, Simona, et al.
Publicado: (2018) -
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019) -
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022) -
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016) -
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)